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Retroviral capsids can be recognized and degraded by a host protein, Trim5a. A recent study inNature (Pertel
et al., 2011) shows that, upon sensing of the retrovirus capsid lattice, Trim5a generates free ubiquitin chains
that activate the TAK1 kinase and downstream innate immune response genes.The cytoplasmic protein Trim5a, encoded
by the Trim5 gene, was discovered in
rhesus macaques as a factor that blocks
HIV-1. However, the human homolog of
this gene does not block HIV-1 effectively.
Since its discovery, Trim5 is found to be
present in most mammals and can block
many retroviruses (and only retroviruses,
thus far), but each species has a unique
specificity toward viral capsids from
different retroviruses. Moreover, Trim5a
exerts a selective pressure on retrovi-
ruses to escape by evolving mutations
in their capsid (Kirmaier et al., 2010).
Because Trim5 has undergone episodes
of adaptive evolution in primates in re-
gions of the protein that recognize the
viral capsid, the evolutionary arms race
between primates and pathogenic retrovi-
ruses is likely an ancient one. The interac-
tion between Trim5a and the retroviral
capsid was initially thought to be a simple
recognition event followed by disruption
of the viral capsid. However, recent work
by the Luban group (Pertel et al., 2011)
now shows that Trim5a sensing of the
retroviral capsid lattice serves an addi-
tional and important role in activating
a signal transduction pathway leading to
the production of inflammatory cytokines
and the establishment of a generalized
antiviral state.
Pathogens are recognized as non-self
by intracellular sensors that in turn trigger
an amplification cascade of host defense
responses against them. Innate immunity
sensors are germline-encoded ‘‘recep-
tors’’ called pattern recognition recep-
tors (PRRs) that recognize microbial
signatures, or ‘‘patterns,’’ which, in a
pathogenic context, are referred to as
pathogen-associated molecular patterns
(PAMPs). Upon sensing PAMPs, PRRs
signal posttranslational activation of ki-
nases (such as TAK1) and transcriptionalactivation of key downstream regulators
such as IFN (interferon) and nuclear factor
kappa B (NF-kB). While PRRs that sense
bacteria mostly recognize chemical and/
or structural features (such as lipopoly-
saccharide, LPS), PRRs that recognize
viral infections most often do so by recog-
nizing nucleic acids that are either in
appropriate intracellular compartments
or have modifications that distinguish
them from host nucleic acids. Recently,
however, Trim21 has been shown to be
a protein sensor of a viral infection by
recognizing antibody-bound virus in the
cytoplasm (Mallery et al., 2010). Also,
a recent publication has shown that
Trim5a recognizes a ‘‘pattern’’ on retro-
viral capsids by assembling hexagonally
on the capsid lattice (Ganser-Pornillos
et al., 2011).
One of the pathways that is activated
after PRR-PAMP interactions is the TAK1
kinase complex involving ubiquitination.
Ubiquitination of substrates requires acti-
vation of ubiquitin (Ub) by a Ub-acti-
vating enzyme (E1), followed by transfer
of Ub to a Ub-conjugating enzyme (E2),
followed by transfer of Ub onto the final
substrate via a Ub-protein ligase (E3).
When cell surface PRRs are stimulated,
factors such as TNF receptor-associated
factor 6 (TRAF6) are recruited to the
receptor. TRAF6 is a RING domain-con-
taining E3 Ub-ligase, which, together
with E2 Ub-conjugating dimers UBC13/
UEV1A, catalyzes the synthesis of K63-
linked polyubiquitin chains (Figure 1).
These chains function as a scaffold to
recruit the TAK1 kinase and regulatory
subunits TAB1, TAB2, and TAB3. Forma-
tion of this kinase complex results in acti-
vation of TAK1 and a subsequent signal
cascade. Trim5a is also a RING do-
main-containing E3 ubiquitin ligase, but
the role of the RING domain in Trim5Cell Host & Microbinhibition of retroviruses has been con-
troversial. Through a series of elegant
cell culture and in vitro experiments
using purified proteins, Pertel et al.
(2011) provide evidence for a model
whereby Trim5a, upon recognition of
retroviral capsids, engages E2 Ub-conju-
gating enzymes UBC13 and UEV1A to
generate free K63-linked polyubiqui-
tin chains which subsequently activate
TAK1. Activation of TAK1 occurs through
direct interactions of Trim5a with the
TAK1 complex consisting of TAK1,
UBC13/UEV1A, and adaptor proteins
TAB2 and TAB3. These events lead to
downstream activation of transcriptional
and posttranslational innate immune re-
sponses (Figure 1). Thus, by linking cap-
sid recognition events to a direct mecha-
nism for activation of innate immune
response genes, Pertel et al. show that
Trim5a acts as a bona fide protein-
sensing PRR.
In some species, such as cows and
rodents, expansions have occurred in
the Trim5 locus resulting in up to eight
homologs in mice (Tareen et al., 2009).
Interestingly, one of these mouse Trim5
homologs, confusingly known as Trim30,
was shown to also be involved in TAK1
signaling, however by degrading TAB2
and TAB3, therefore resulting in an oppo-
site effect (Shi et al., 2008) as that
described for human Trim5a. These re-
sults may complicate the use of mice as
models for testing the in vivo relevance
of this locus in innate immunity to patho-
genic infections.
Curiously, Trim5a also has a role in
signaling resulting in antiviral conse-
quences that are independent of retroviral
capsid recognition. Knockdown of Trim5a
in myleoid cells blunted the transcriptional
responses of these cells to LPS, a PAMP
derived from gram-negative bacteria.e 9, May 19, 2011 ª2011 Elsevier Inc. 349
Figure 1. Trim5a Functions as a PRR to Activate Innate Immunity
Signaling
Upon sensing viral capsid, Trim5a, together with E2-conjugating enzymes
UBC13/UEV1A, catalyzes the synthesis of K63-linked polyubiquitin (poly-Ub)
chains. These chains serve as a scaffold to recruit the TAK1 kinase complex
consisting of TAK1 and the regulatory proteins TAB2 and TAB3. These events
result in activation of TAK1 via its autophosphorylation on Thr187, subse-
quently activating transcriptional regulators such as NF-kB. Trim5 also plays
a role in LPS signaling via the Toll-like receptor 4.
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with LPS leads to a general-
ized antiviral state, and
knockdown of Trim5a par-
tially relieves this block to
a range of viruses that are
not directly recognized by
Trim5a (Pertel et al., 2011).
Another study had also
shown that overexpression
of Trim5a activates NF-kB in
the absence of retroviral cap-
sid recognition (Tareen and
Emerman, 2011). These re-
sults put Trim5a as a central
player in generalized innate
immune responses. Indeed,
although HIV-1 is poorly re-
cognized by human Trim5a,
this protein could nonethe-
less be important in HIV-1
progression, since low levels
of LPS are associated with
chronic immune activation
in AIDS patients (Brenchley
et al., 2010). Moreover, there
are human polymorphisms
in Trim5, and one in partic-
ular, a mutation in the RINGdomain (H43Y), that has been associated
with HIV progression in some studies (van
Manen et al., 2008). It will be important to
look at the role of human polymorphisms
in Trim5 that might have subtle dif-
ferences in signaling cascades in the
clearance of pathogens in chronic and
acute infections. Furthermore, as Trim5350 Cell Host & Microbe 9, May 19, 2011 ª20polymorphisms have also been associ-
ated with the degree of responsiveness
to Rubella vaccination (Ovsyannikova
et al., 2010), it is possible that finding
ways to artificially engage Trim5a might
prove to be a useful strategy to induce
responses in the context of candidate
HIV vaccines.11 Elsevier Inc.REFERENCES
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